Research programme: autoimmune disorders therapeutics - Mount Tam Biotechnologies

Drug Profile

Research programme: autoimmune disorders therapeutics - Mount Tam Biotechnologies

Alternative Names: TAM-01; TAM-02; TAM-03

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotica Technology; University of Cambridge
  • Developer Mount Tam Biotechnologies
  • Class Antineoplastics; Macrolides; Neuroprotectants; Polyketides
  • Mechanism of Action Immunosuppressants; MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Systemic lupus erythematosus
  • Research Cancer; Multiple sclerosis

Most Recent Events

  • 22 Feb 2018 Mount Tam Biotechnologies receives patent allowance for TAM 01 in Europe
  • 22 Feb 2018 Mount Tam Biotechnologies plans to submit IND application with the US FDA for Systemic lupus erythematosus
  • 21 Apr 2017 Buck Institute for Research on Aging receives patent allowance for TAM 01 in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top